Please provide your email address to receive an email when new articles are posted on . Early cytomegalovirus reactivation after allogeneic stem cell transplantation induced cytomegalovirus ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — The novel antiviral agent letermovir appeared effective for primary cytomegalovirus prevention among ...
Often, clinicians and scientists know the mechanism of how a drug or intervention works by the time it makes it into patients in the form of a clinical trial. Yet sometimes, an intervention is shown ...
The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) ...
Hosted on MSN
Q&A: Raising awareness about cytomegalovirus colitis
Cytomegalovirus (CMV), a common virus in the Herpesviridae family, infects approximately half of all adults in the United States, most of whom experience mild or no symptoms. While the virus usually ...
Reactivation of human cytomegalovirus (HCMV) from latency is a major health consideration for recipients of stem-cell and solid organ transplantations. With over 200,000 transplants taking place ...
SAN DIEGO, Sept. 13, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its ...
In a recent study published in the journal Nature Communications, researchers investigate the effects of human cytomegalovirus (CMV) reactivation on breast milk composition. Study: Human ...
SAN DIEGO, April 14, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the issuance of European Patent EP1587816, which extends coverage for TransVax™, the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback